Lin Patrick 4

What Happened Lin Patrick, Chief Business & Strategy Officer at Processa Pharmaceuticals (PCSA), made an open-market purchase of 1,582 shares on 2026-05-29 at $2.57 per share, for a total cost of approximately $4,066. This was a direct purchase (transaction code P); purchases are often viewed as a more informative insider action than routine sales, though motivations are not disclosed.

Key Details

• Transaction date and price: 2026-05-29 — 1,582 shares at $2.57 each.
• Total value: ≈ $4,066.
• Transaction type: Open-market purchase (SEC code P).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing date: 2026-06-01 (filed timely; within required reporting window).
• No footnotes provided in the supplied details (e.g., no 10b5-1 plan, tax withholding, or gift indicators noted).

Context This was a straightforward share purchase, not an option exercise or award. The amount is relatively small; while insider buys can be a positive signal, they do not guarantee future stock performance. Retail investors should consider this alongside broader company fundamentals and other insider activity.